Los Angeles Capital Management LLC Sells 5,642 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Los Angeles Capital Management LLC reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 110,630 shares of the biopharmaceutical company’s stock after selling 5,642 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.09% of Halozyme Therapeutics worth $6,332,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of HALO. Janney Montgomery Scott LLC boosted its position in shares of Halozyme Therapeutics by 28.7% during the 1st quarter. Janney Montgomery Scott LLC now owns 16,454 shares of the biopharmaceutical company’s stock valued at $669,000 after acquiring an additional 3,666 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Halozyme Therapeutics by 54.6% in the 1st quarter. GSA Capital Partners LLP now owns 11,217 shares of the biopharmaceutical company’s stock valued at $456,000 after buying an additional 3,962 shares in the last quarter. Swiss National Bank grew its position in Halozyme Therapeutics by 0.3% in the first quarter. Swiss National Bank now owns 260,900 shares of the biopharmaceutical company’s stock valued at $10,613,000 after acquiring an additional 900 shares during the period. US Bancorp DE raised its stake in Halozyme Therapeutics by 64.6% during the first quarter. US Bancorp DE now owns 13,912 shares of the biopharmaceutical company’s stock worth $566,000 after acquiring an additional 5,458 shares in the last quarter. Finally, ProShare Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 4.9% during the first quarter. ProShare Advisors LLC now owns 38,662 shares of the biopharmaceutical company’s stock valued at $1,573,000 after acquiring an additional 1,794 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total value of $620,300.00. Following the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at approximately $10,778,084.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total transaction of $620,300.00. Following the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $10,778,084.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the transaction, the director now owns 69,874 shares of the company’s stock, valued at $4,031,729.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 79,881 shares of company stock valued at $4,612,634. Company insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on HALO shares. Morgan Stanley increased their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. JMP Securities boosted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Finally, TD Cowen increased their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $61.09 on Tuesday. The firm’s 50 day simple moving average is $56.56 and its 200 day simple moving average is $53.03. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a market capitalization of $7.77 billion, a price-to-earnings ratio of 20.23, a P/E/G ratio of 0.56 and a beta of 1.29. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.